The purpose of the present study was to purify and characterise the antigen identified by mAb 83D4. The antigen was isolated from different sources, and purified antigen was analysed by biochemical and immunological methods. Moreover, the reactivity of mAb HMFG-1 (TaylorPapadimitriou et al., 1981) defining the PEM antigen and of mAb B72.3 and CC49 (Muraro et al., 1988) , defining the TAG-72 antigen, with the 83D4 purified antigen was investigated.
Monoclonal antibody (mAb) 83D4 is produced by a murine hybridoma generated by immunisation with cell suspensions from a paraffin block of human breast carcinoma tissue.
MAb 83D4 was reactive with three breast cancer cell lines (MCF7, T47D and H466B) and with breast cancer tissue in paraffin and frozen sections, but no reactivity with normal breast epithelium was detected (Pancino et al., 1990a) . Immunohistochemical studies on a large panel of normal and tumoral human tissues (Charpin et al., manuscript in preparation) showed mAb 83D4 to be reactive with other carcinomas including ovarian, endometrial, pancreatic and colonic adenocarcinomas. In normal tissues, 83D4 reactivity was limited to colon, stomach and endometrium. A few other mAb directed against breast-cancer-associated antigens have been reported which are also not reactive with normal breast tissues: B72.3, directed against a high molecular weight (MW) glycoprotein (Colcher et al., 1981 & Thor et al., 1986 ; 451B7 and 452F2 recognising a 210 kDa protein (Frankel et al., 1985) ; SM-3 raised to the core protein of a milk mucin, PEM, purified with mAb HMFGI (Burchell et al., 1987) ; H23 which was generated by immunisation with a cellular fraction from T47D breast cancer cell line and is reactive with a 68 kDa glycoprotein (Keydar et al., 1989) . A cDNA clone isolated using mAb H23 was shown to have sequences corresponding to a PEM gene domain (Wreschner et al., 1990) . All these mAb were produced using immunogens different from that used to generate 83D4. Only mAb B72.3 was reported to have a distribution of reactivity in human tissues similar to that found with 83D4 (Thor et The purpose of the present study was to purify and characterise the antigen identified by mAb 83D4. The antigen was isolated from different sources, and purified antigen was analysed by biochemical and immunological methods. Moreover, the reactivity of mAb HMFG-1 (TaylorPapadimitriou et al., 1981) defining the PEM antigen and of mAb B72.3 and CC49 (Muraro et al., 1988) , defining the TAG-72 antigen, with the 83D4 purified antigen was investigated.
Materials and methods mAb
IgM mAb 83D4 was generated by immunisation of Balb/c mice with cell suspensions from formalin-fixed paraffinembedded sections of an invasive human breast carcinoma as described in detail elsewhere (Pancino et al., 1990a) . The antibody was purified from ascitic fluid by dialysis against demineralised water (Garcia-Gonzales et al., 1988) . Precipitated antibody was resuspended in 0.1 M Tris-HCI pH 8, 1 M NaCl and dialysed against the appropriate buffer.
Control antibodies produced in our laboratory were BIN, an IgM reactive with a nuclear protein; CA4, an IgM raised to a human milk cell glycoprotein (Pancino et al., 1991) and 1BE12, an IgM mAb against a breast-cancer-associated glycoprotein (Pancino et al., 1990b) . Culture supernatant containing mAb HMFG-1 (Taylor-Papadimitriou et al., 1981) was a generous gift of Dr J. Taylor-Papadimitriou, Imperial Cancer Research Fund, London, GB. MAbs B72-3 (Colcher et al., 1981) and CC49 (Muraro et al., 1988) raised to a tumour-associated glycoprotein (TAG-72) were kindly supplied by Dr J. Schlom, National Cancer Institute, Bethesda, MD, in the form of ascitic fluids. Purification of HMFG-1 concentrated supernatant and of B72.3 and CC49 ascitis was performed using the 'Affi-Gel' protein A Maps-2 kit (Bio-Rad). IgGI immunoglobulins were eluted at pH 6 for B72.3 and CC49 and at pH 5 for HMFG-1 and dialysed against 0.1 phosphate buffer pH 7.
MAbs 83D4, B72-3 and CC49 were labelled with 1251 using lodogen by P. Mouly, CIS Bioindustrie, France. Specific activity was 3.70;LCi Ag-' for 83D4 and 3.251iCipg-g for B72.3 and CC49.
Antigen sources
The MCF7 breast carcinoma cell line (Soule et al., 1973) was cultured in Dulbecco's modified Eagle's medium supplemented with 10% foetal calf serum, 2 mM L-glutamine, 100IU ml' penicillin and 50ligml-' streptomycin. Cell cytosol and membrane fractions were prepared from MCF7 cells as described (Pancino et al., 1989) . Membranes were extracted with PBS 0.5 NP-40 containing proteases inhibitors (1 mM PMSF, two kallikrein inhibitor units ml-' bovine aprotonin).
Breast and colon carcinoma tissues were frozen in liquid nitrogen. Tissues were homogenised as described (Pancino et al., 1989) in 20 mM Tris-HCI pH 7.4, 100 mM CaCl, 5 mM MgCl2, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF and two kallikrein inhibitor units ml-' bovine aprotonin.
Pleural effusion fluids from patients with metastatic breast carcinomas were kindly provided by M. Beuzelin, Centre Rene Hugenin, St Cloud (France).
The protein concentration of each sample was determined by Lowry's method (Lowry et al., 1951) .
Preparation of human milk fat globule membanes (HMFGM) Crude HMFGM were prepared from fresh human milk as described (Keenan et al., 1970) . After centrifugation at 100,000g for 1 h, the HMFGM pellet was resuspended in PBS 0.5% NP40, containing protease inhibitors. The protein concentration was determined by Lowry's method.
Perchloric acid (PCA) fractionation of the samples The MCF7 crude membrane fraction, breast and colon carcinoma tissue extracts and pleural effusion fluids were subjected to perchloric acid precipitation at 4°C (0.6 M final concentration) using the method of Delong and Davidson (1981) . PCA soluble fraction containing 83D4 reactive material was neutralised with 1.2 M KOH, dialysed against PBS and concentrated (PCA samples).
Sodium dodecyl sulphate polyacrylamide gel electrophesis (SDS-PA GE) and immunoblotting Proteins from PCA samples were precipitated with cold acetone and the pellet was solubilised in 9.5 M urea, 4% NP40, 5% ,B-mercaptoethanol and 2% SDS. Samples were analysed by SDS-PAGE (Laemli, 1970) in 3-10 polyacrylamide gels using a stacking gel of 3% acrylamide.
After electrophoresis, proteins were transferred to nitrocellulose paper according to Towbin et al. (1979) at 0.3 amp overnight in 20 mM Tris HCI pH 8.3, 192 mM glycine, 10% methanol. The immunological reaction was performed as described (Pancino et al., 1989 Periodate and neuraminidase treatment Periodate oxidation of the immunopurified antigen was performed by the method described by Woodward et al. (1985) Microtitre wells coated with the antigen were incubated with NaIO4 (Merck) in 50 mM sodium acetate buffer pH 4.5, at concentrations ranging from 0.1 to 20 mM for I h at room temperature in the dark. After washing, plates were incubated with 1% glycine in PBS for 30min. ELISA with 83D4 was then performed as described above to determine immunoreactivity.
Immunopurified antigen coated in microtitre plates was subjected for 1 h at 37°C to enzymatic digestion with 6.25-100 IU ml-' neuraminidase from vibrio cholera (Boehringer) or from Clostridium perfringens (SIGMA, type X) in 0.05 M acetate buffer pH 5.5, 2 mM CaC12. Control wells were incubated with the same buffer. After treatment, plates were washed and ELISA was performed to assess 83D4 reactivity.
Protease digestion
Microplates coated with 83D4 immunopurified antigen were exposed for I h at 37C to enzymatic treatment with trypsin (Flow Laboratories) at concentrations ranging from 0.3 to 2.5 mg ml-', or subtilysin (SIGMA) at concentrations of 0.125 to 0.5 mgml'1, in 10mM Tris pH8, 2mM CaCI2.
Control wells were incubated with the same buffer. Plates were then washed and residual antigenic activity was determined by ELISA.
Double determinant radioimmunoassay (DD-RIA)
A total of 100tl per well of mAb (lOfigml' in 0.1 M carbonate buffer pH 9.6) were incubated in microtitre plates for 2 h at 37°C and overnight at 4°C. Plates were washed with PBS 0.1% Tween-20 and blocked with 3% BSA in PBS for 1 h at 37°C; 100 jil of immunopurified antigen at different dilutions in PBS were added to the wells and incubated for 1 h at 37°C. Control wells without antigen were incubated with the same buffer. After three washes, 100 gtlI of 12511 labelled 83D4 antibody diluted in PBS, 0.1% Tween, 1% BSA (150,000 c.p.m./well) were added to the wells and incubated for 2 h at 37°C. Finally after five washes, wells were cut and bound radioactivity was determined. The 1251I labelled mAb B72-3 and CC49 were also used as second antibodies under the same conditions as 83D4. Working dilutions of purified antigen were determined by DD-RIA with mAb 83D4 for each sample. All essays were done in duplicate.
Inhibitory double determinant radioimmunoassay
Plates were coated with mAb 83D4 or with mAb CC49 as described above for DD-RIA. After blocking with 3% BSA in PBS, antigen was incubated for 1 h at 37°C. After plate washing, 50 fLd of '25I-labelled antibodies (250 ng ml-', corresponding to 150,000 c.p.m. per well) were mixed with increasing concentrations of unlabelled antibodies (ranging from 1 ng ml-' to I05 ng ml-' final concentrations) and added in duplicate to wells. Following 2 h incubation at 37°C, plates were extensively washed with 0.1% Tween 20 in PBS and binding of '25I-labelled antibody was measured. Percent inhibition as compared to a control buffer sample was determined. Time (minutes) Figure 3 Size exclusion chromatography of 83D4 immunoaffinity purified antigen from a pleural effusion fluid on FPLC with Superose-6 HR column. Flow rate: 0.5 ml min-'. The eluate was monitored in absorbance at 280 nm and the collected fractions were tested for 83D4 reactivity in ELISA. indicating that a good antigen purification degree has been obtained. 83D4 antigen was also isolated from MCF7 membrane extracts, using the same method. Figure 5 ).
Biochemical analysis of 83D4 reactive antigen
The immunopurified antigen was subjected to proteolytic digestion with trypsin and subtilysin, resulting in a sharp reduction in 83D4 binding. Figure 6a shows that trypsin gradually reduced 83D4 reactivity up to 90% at a 2.5 mg ml' concentration, while subtilysin had already abolished antibody binding at the first concentration tested (0.125 mg ml-').
To determine whether carbohydrate structures take part in the 83D4 antigenic determination, the antigen was subjected to sodium periodate oxidation. Figure 6b shows that 83D4 binding was reduced after Na periodate treatment, up to an 85% reduction at 20 mM metaperiodate concentrations. In contrast, antigenic reactivity was not affected by treatment with Neuraminidase from Vibrio cholera or from Clostridium perfringens (Figure 6c ).
Repeated epitope expression of 83D4 reactive antigen
Immunoaffinity-purified antigen was tested for its reactivity in a double determinant radioimmunoassay. Antigen purified from breast cancer pleural effusion and colon carcinoma HMFGJ reactivity with the 83D4 defined antigen To investigate the expression of HMFG1 epitope on 83D4 defined antigen an ELISA was performed using the immuno/ FPLC (Vo) purified 83D4 antigen from MCF7 membrane extracts. No significant reactivity was detected with HMFG1, which conversely bound to the MCF7 PCA sample from which antigen had been isolated (Figure 8 ). Immunoblotting of MCF7 PCA sample and purified antigen confirmed these results (not shown).
B72-3 and CC49 reactivity with 83D4 defined antigen MAb B72-3 directed against a high MW carcinomaassociated mucin TAG-72, and the second-generation mAb CC49 raised to purified TAG-72 were tested for reactivity to the 83D4 defined antigen. ELISA assays on the immuno/ FPLC (Vo) purified 83D4 antigen from MCF7 membranes or pleural effusion fluid showed CC49 binding to the antigen, while very weak reactivity was detected with B72-3 (not shown). Moreover FPLC filtration fractions of immunopurified 83D4 antigen were tested for reactivity with mAbs 83D4 and CC49: antigenic activity was found in the Vo fraction as expected, while low molecular species were unreactive with both antibodies. Immunoblotting of PCA sample from a pleural effusion fluid was then performed to compare reactivity patterns of mAbs 83D4 and CC49. Reactive bands of high MW with similar electrophoretic mobility were detected by the two antibodies (Figure 9 ). In further RIA experiments immunopurified antigens were used. 83D4 antigens from pleural effusion fluid, breast carcinoma and colon carcinoma extracts were tested in a double determinant RIA for binding to mAb B72-3 and CC49. (0) tionship between antigenic determinants of these antibodies. Similar results were found with antigens of both origins. No competition with 83D4 was shown by mAb B72-3 (results not shown). CC49 competed at 35% for the highest concentrations (50 and 100 1g ml-' of CC49) for the colon-cancerderived antigen (Figure 10a ). In the reciprocal mAb CC49 competition RIA, 83D4 competed at 65% for maximal concentrations ( Figure 10b ).
Discussion
MAb 83D4 was produced by immunising mice with paraffin sections of an invasive breast carcinoma. It has previously been shown to react with both fixed and paraffin-embedded and frozen breast carcinoma tissues (Pancino et al., 1990a) .
No reactivity was detected with normal breast. These studies indicated that 83D4 identifies a native antigen not affected by fixation and paraffin embedding procedures, and that the antigen is well expressed in breast cancer, but is absent in normal mammary epithelium.
In the present work, the antigen was detected in MCF7 breast cancer cell line membrane extracts, in primary breast carcinoma and in colon carcinoma extracts. The antigen was also detected and then isolated from a pleural effusion fluid of patients with metastatic breast carcinoma, indicating that it can be released in soluble form from breast cancer cells. No detectable expression of the antigen was found in human milk components. Immunoblotting analysis showed that 83D4 epitopes are carried by heterogeneous acidic proteins of high MW (>300 kDa). The antigen, soluble in PCA, was purified using immunoaffinity chromatography, subsequent gel filtration and anion exchange chromatography. 3.70fiCigg-g; ACigg-'; **c.p.m. bound. Ashall et al., 1982; Hilkens et al., 1984; Papsidero et al., 1984; Sekine et al., 1985; Price et al., 1986; Linsley et al., 1986; Stacker et al., 1989) . cDNA clones coding for the core protein of this mucin, termed Polymorphic Epithelial Mucin (PEM), were recently isolated and the amino acid sequence was fully determined (Gendler et al., 1988 and . We used mAb HMFG1, which defines the PEM antigen, to study the relationship with 83D4 antigen: no binding of HMFG1 to 83D4 purified antigen could be detected by ELISA and immunoblotting.
The glycoprotein nature of the antigen recognised by 83D4, its binding to WGA, its apparent MW and heterogeneity and its selective reactivity for breast tumours vs normal breast tissue are similar to the characteristics of a pancarcinoma-associated glycoprotein TAG-72 defined by mAb B72.3, generated using a membrane preparation from a mammary carcinoma metastasis (Colcher et al., 1981) . It was thus important to determine whether a relationship of 83D4 antigen to TAG-72 exists. MAbs B72.3 and colon cancer-purified TAG-72 second generation mAb CC49 (Muraro et al., 1988) were used for this study. 83D4 immuno/FPLC (Vo) purified antigen bound the two antibodies in ELISA and immunoblotting showed similar reactivity patterns of 83D4 and CC49 antibodies. Since the reactivity of mAb B72.3 and CC49 has been shown to vary with different tumour extracts of breast and colon carcinomas (Muraro et al., 1988) , three different sources of 83D4 defined antigen were used for further cross-reactivity studies. Differential binding of mAb B72.3 and CC49 to 83D4 defined antigen was found using the antigen purified from pleural effusion fluid, breast carcinoma or colon carcinoma. B72.3 bound weakly to effusion fluid and coloncarcinoma-derived antigens and very weakly to the breastcarcinoma-derived antigen, while CC49 bound weakly to antigens of breast cancer origin, but stronger to the coloncancer-derived antigen. These results indicate that 83D4 defined antigen carries epitopes reactive with B72.3 and CC49, which may vary quantitatively in different sources, CC49 epitope being most expressed in colon carcinoma. MAb B72.3 and CC49 both react with the carbohydrate epitopes Kjeldsen et al., 1988; Sheer et al., 1988) and the 83D4 epitope also appears to involve sugar moieties. A competition RIA showed that B72.3 did not compete with 83D4, and that CC49 only partially inhibited 83D4 binding to its antigen. The failure of B72.3 to compete with 83D4 could be expected, since the B72.3-reactive epitope has been shown to be a sialosyl-Tn structure (Kjeldsen et al., 1988) sensitive to neuraminidase digestion (Kjelden et al., 1988 , while the 83D4 epitope was not affected by neuroaminidase treatment. There are several possible interpretations for the partial competition between CC49 and 83D4: the two epitopes may be distinct, but in physical proximity to each other; they may be only partially overlapping; or partial inhibition may have resulted from conformational changes induced by antibody binding. It is possible that conformational changes in the antigen molecule or steric hindrance of the binding site caused by 83D4 IgM immunoglobulin may partially account for the asymmetric pattern of cross-competition between IgM 83D4 and IgGI CC49 (CC49, at the highest concentrations, inhibited 35% of 83D4 binding to antigen; 83D4 inhibited 65% of CC49 binding in reciprocal competition RIA).
In the summary, the results reported above suggest that the antigen identified by 83D4 shares common antigenic activity with the TAG-72 antigen identified by B72.3 and CC49, but expression of reactive epitopes varies with the antigen source. The antigenic determinant identified by 83D4 appears to be different from those defined by B72.3 and CC49. The relationship shown to exist between the 83D4 reactive antigen and the TAG-72 antigen is suggestive of the hypothesis that they may belong to the same family of related, high MW tumour-associated glycoproteins. The difference in immunoreactivity found with 83D4 in comparison with B72.3 or CC49 may result from expression of a different number of carbohydrate epitopes on the same protein molecule, caused by varying degrees of glycosylation. However, it cannot be excluded that differential reactivity may be due to different proteins carrying the epitopes on the oligosaccharide side chains. It is worth noting that hybridoma-secreting mAb 83D4 was generated in a completely different way from B72.3 and CC49. Epitope analysis and mapping of 83D4 defined antigen and TAG-72 antigen, as well as cloning of coding genes, would clearly define their relationship and indicate whether these molecules constitute a new family of carcinoma-associated glycoprotein antigens. At present, it is known that mAb B72.3 identifies a sialyl-Tn epitope, and CC49 has been claimed to react with other oligosaccharides; this study demonstrates that 83D4 identifies a novel epitope and that sugar moieties take part in it. A number of tumour-associated glycoprotein carbohydrate epitopes have been detected by mAb, and some of them have been characterised, including antigen reactive with the mAb 19-9 directed to a sialyl-Lea carbohydrate chain carried on a gastrointestinal-cancer-associated mucin (Magnani et al., 1983) , and the Tn antigen identified by mAb NCC-LU-35 and NCC-LU-81 raised against squamous lung carcinomas (Hirohashi et al., 1985) . Aberrant glycosylation of glycoprotein antigens is a common phenomenon in human cancers (reviewed in Hakomori, 1989) . Studies to define the structure of the 83D4 reactive epitope and its function are now required to elucidate its relationship with oncogenic transformation.
